Clinical trial · Interventional
Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck Cancer
Hypofractionated Radiotherapy and Concurrent Cisplatin for Locally Advanced Head and Neck Cancer: A Feasibility Trial
NCT03194061CI-TRIAL-00031280HIPOCPunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the feasibility of hypofractionated radiation therapy and concomitant chemotherapy with cisplatin for locally advanced head and neck cancer in a high volume brazilian center.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiotherapy; Complications | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated Radiotherapy | Radiation | — | UNRESOLVED |
| Weekly cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hypofractionated chemoradiation
- description
- 20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
- interventionNames
- Radiation: Hypofractionated Radiotherapy
- Drug: Weekly cisplatin
Primary outcomes (2)
- measure
- To evaluate the rate of patient who could complete the treatment.
- timeFrame
- up to 5 years after patient accrual
- description
- The treatment is considered completed when patients receive at least 90% of radiation dose (49,5Gy) with a cumulative cisplatin dose of 105mg/m2 or more (3 of 4 cycles) and the treatment duration is inferior to 35 consecutive days.
- measure
- To evaluate the rate of participants with treatment-related adverse events
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven squamous cell carcinoma of oropharynx, larynx and hypopharynx. * Stage III an IV, with no distant metastasis. * ECOG performance status 0-2. * Adequate renal and liver function. * Good status for radical treatment Exclusion Criteria: * Other oncologic treatment before * Distant metastasis * History of previous malignancy
References
Publications (1)
- DERIVEDJacinto AA, Batalha Filho ES, Viana LS, De Marchi P, Capuzzo RC, Gama RR, Boldrini Junior D, Santos CR, Pinto GDJ, Dias JM, Canton HP, Carvalho R, Radicchi LA, Bentzen S, Zubizarreta E, Carvalho AL. Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma. BMC Cancer. 2018 Oct 23;18(1):1026. doi: 10.1186/s12885-018-4893-5. PMID 30352576